Bibliography

  1. Izzedine H. Anti-VEGF Cancer Therapy in Nephrology Practice. Int J Nephrol. 2014;2014:143426.
  2. Izzedine H, Brocheriou I, Deray G, Rixe O. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant. 2007;22(5):1481-1482.
  3. Izzedine H, Sene D, Hadoux J, et al. Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment? Ann Oncol. 2011;22(2):487-490.
  4. Abudayyeh A SU, Hanna RM. Renal Protection, Chapter 26:Anti VEGF toxicity. Vol Chapter 26. 1 ed. UK: Oxford; 2018.
  5. Hanna R, Tran N, Patel SS, et al. Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use. Frontiers in Medicine-Nephrology. 2020.
  6. Hanna RM, Abdelnour L, Hasnain H, Selamet U, Kurtz I. Intravitreal bevacizumab-induced exacerbation of proteinuria in diabetic nephropathy, and amelioration by switching to ranibizumab. SAGE Open Access Medical Case Reports. 2020.
  7. Hanna RM, Abdelnour L, Zuckerman JE, et al. Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab. SAGE Open Med Case Rep. 2020;8:2050313X20952650.
  8. Hanna RM, Barsoum M, Arman F, Selamet U, Hasnain H, Kurtz I. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019.
  9. Hanna RM, Lopez E, Hasnain H, et al. Three patients with injection of intravitreal vascular endothelial growth facto inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2018.
  10. Hanna RM, Lopez E, Wilson J, Barathan S, Cohen AH. Minimal change disease onset observed after bevacizumab administration. Clin Kidney J. 2016;9(2):239-244.
  11. Hanna RM, Selamet U, Hasnain H, et al. Development of Focal Segmental Glomerulosclerosis and Thrombotic Microangiopathy in a Liver Transplant Patient on Sorafenib for Hepatocellular Carcinoma: A Case Report. Transplant Proc. 2018;50(10):4033-4037.
  12. Nobakht N. NHA, Kamgar M., Abdelnour L., Rastogi A., Hanna R.M. Development of Collapsing Focal and Segmental Glomerulosclerosis in a Patient Receiving Intravitreal Vascular Endothelial Growth Factor Blockade. Kidney Int-Rep. 2019.
  13. Phadke G, Hanna RM, Ferrey AJ, et al. Review of intravitreal vascular endothelial growth factor inhibitor toxcitiy, and report of collpasing focal and segmental sclerosis with thrombotic microangiopathy in a patient with age-related macular degeneration. Clin Kidney J. 2021.
  14. Shye M, Hanna RM, Patel SS, et al. Worsening Proteinuria and Renal Function after Intravitreal Vascular Endothelial Growth Factor Blockade for Diabetic Proliferative Retinopathy. Clin Kidney J. 2020.
  15. Cheungpasitporn W, Chebib FT, Cornell LD, et al. Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts. Transplantation. 2015;99(11):2382-2386.
  16. Diabetic Retinopathy Clinical Research N, Scott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860-1867.
  17. Georgalas I, Papaconstantinou D, Papadopoulos K, Pagoulatos D, Karagiannis D, Koutsandrea C. Renal injury following intravitreal anti-VEGF administration in diabetic patients with proliferative diabetic retinopathy and chronic kidney disease–a possible side effect? Curr Drug Saf. 2014;9(2):156-158.
  18. Jamrozy-Witkowska A, Kowalska K, Jankowska-Lech I, Terelak-Borys B, Nowosielska A, Grabska-Liberek I. [Complications of intravitreal injections–own experience]. Klin Oczna. 2011;113(4-6):127-131.
  19. Kenworthy J-A, Davis J, Chandra V, Clark JB, Desmond M. Worsening Proteinuria Following Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema. 2019;3(1):54-56.
  20. Khneizer G. A-TA, Bastani B Self limited membranous nephropathy after intravitreal nephropathy after intravitreal bevacizumab therapy for age related macular degeneration J Nephropathol. 2017;6(3):134-137.
  21. Miwako Yoshimoto NT, Takayuki Yoshimoto,Shun Matsumoto. Hypertensive cerebral hemorrhage with undetectable plasma VEGF after intravitreal injection of aflibercept for diabetic macular edema. In:2020.
  22. Morales E, Moliz C, Gutierrez E. Renal damage associated to intravitreal administration of ranibizumab. Nefrologia. 2017;37(6):653-655.
  23. Pelle G, Shweke N, Duong Van Huyen JP, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis. 2011;57(5):756-759.
  24. Perez-Valdivia MA, Lopez-Mendoza M, Toro-Prieto FJ, et al. Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab. Nefrologia. 2014;34(3):421-422.
  25. Sato T, Kawasaki Y, Waragai T, et al. Relapse of minimal change nephrotic syndrome after intravitreal bevacizumab. Pediatr Int. 2013;55(3):e46-48.
  26. Touzani F, Geers C, Pozdzik A. Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury. Case Rep Nephrol. 2019;2019:2919080.
  27. Tran T. Intravitreal VEGF Inhibitor Causing Allergic Interstitial Nephritis. AJKD [abstract only]. 2017;69(4):A99.
  28. Yen W, Zhang Pl. Intravitreal Injection of Avastin (IIA) Over Time Can Be Associated with Thromobtic Microangiopathy (TMA) in the Native Kidney. ASN Kidney Week; 2019; Washington DC.
  29. Hanna RM, Ahdoot RS, Kim MS, Jhaveri KD, Kalantar-Zadeh K, Kurtz IB. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. Curr Opin Nephrol Hypertens. 2022;31(1):47-56.